Icon

Trileptal - (300mg/5ml; Oral suspension)

Oxcarbazepine Novartis
300mg/5ml; Oral suspension
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
More Than 5
More Than 5
Indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in pediatric patients aged 4 years and above with epilepsy, and as adjunctive therapy in pediatric patients aged 2 years and above with partial seizures.
Yes
***, ***** *** ****** ***** **** ** *** *** ***** ********* ******* ***** *********. ********* ** ******** ****** ** *** *****, ** *** *** **** ***********, *** *** ******** ******* ***. *****, ***** *** ****** ***** ******** *** ******* ** ******. **, *** ******'* *** **** *********** ** *********.
Trileptal Patent 1 Patent 2
*** ****** *** ********* *** *********
***** *** ********* *** *********
****** *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** ****** *** \ ** ** *** ********* ******** *** ****** *** ****
***** ** \ ** ** *** ********* ******** ******** ** *** *, ****
****** ** \ ** ** *** ********* ******** ******** ** **** **, ****
  1. *** **, **** : *** ***** **** ** **** ****** '*** . ** *** ***** *********.
  2. *** **, **** : *** *** ***** ********.
  3. *** **, **** : ****** *** ******** *** ******** *******.
  4. *** *, **** : ***** *** ******** *** ******** *******.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.